Mycophenolate mofetil

Suppliers

Names

[ Name ]:
Mycophenolate mofetil

[Synonym ]:
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)-
6-((7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl))-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester
Cellcept
MYCOPHENOLATE MOFETIL EP IMPURITY A (= USD RC A)
2-(Morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
Mycophenolate mofetil (CellCept)
Mycophenolatemofetil
2-morpholin-4-ylethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
MYCOPHENOLATE MOFITILE
MYCOPHENOLATE
2-(Morpholin-4-yl)ethyl-(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-methylhex-4-enoat
RS 61443-190
MYCOPHENOLATE MOFETIL FOR PEAK IDENTIFICATION, EP STANDARD
2-morpholin-4-ylethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
(E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester
(4E)-6-(4-hydroxy-6-méthoxy-7-méthyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-méthylhex-4-énoate de 2-morpholin-4-yléthyle
MYCOPHENALATE MOFETIL
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-(4-Morpholinyl)ethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-4-hexenoate
2-(4-Morpholinyl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-4-hexenoate
MYCOPHENOLATE MOFETIL(CELLCEPT)
(E)-2-morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
2-Morpholin-4-ylethyl-(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-methylhex-4-enoat
Mycophenolate mofetil
MFCD00867568
Mycophenolic acid morpholinoethyl ester

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
637.6±55.0 °C at 760 mmHg

[ Melting Point ]:
95-96ºC

[ Molecular Formula ]:
C₂₃H₃₁NO₇

[ Molecular Weight ]:
433.495

[ Flash Point ]:
339.4±31.5 °C

[ Exact Mass ]:
433.210052

[ PSA ]:
94.53000

[ LogP ]:
3.15

[ Vapour Pressure ]:
0.0±2.0 mmHg at 25°C

[ Index of Refraction ]:
1.557

[ Storage condition ]:
Store at RT

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H400

[ Precautionary Statements ]:
P273

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R22

[ Safety Phrases ]:
22

[ RIDADR ]:
UN 3077 9 / PGIII

Articles

Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.

Transplantation 99(1) , 180-6, (2015)

Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing st...

Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

J. Am. Coll. Surg. 219(6) , 1134-42.e2, (2014)

Thoracic fluid retention after living donor liver transplantation (LDLT) has various negative consequences, including atelectasis, pneumonia, and respiratory distress or failure.We analyzed the clinic...

The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.

Clin. Transplant. 28(8) , 845-54, (2014)

Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and o...